Quest Diagnostics shares rose more than 8% last week after the medical testing leader boosted its full-year sales and profit forecast. Second-quarter revenue jumped 10% year over year to $3 billion, driven by partnerships with Corewell Health and Fresenius Medical Care, along with gains in its direct-to-consumer business and wellness-related sales. Adjusted earnings per share leaped 19% to $3.12, aided by automation and AI investments that improved lab efficiency. Management now projects full-year revenue of roughly $12 billion and adjusted earnings per share of $11.05 to $11.25.
Quest Diagnostics IncorporatedRaised full-year sales and profit forecast, with strong Q2 earnings growth.